immagebio.com
About company
Immage Biotherapeutics Corp. (OTC: IMMG) has been founded on the foundational understanding that many cancers can be treated via the harnessing the power of the human immune system. The pipeline of the company consists of a DNA viral vaccine construct that is target to tumors that expresses the Melanoma antigen family – A (MAGE-A) antigen. The company has a pipeline of therapeutics that has a high success probability because our treatment targets patient population medical needs are not being met at this time. Our leading pipeline is a universal vaccine that can be used for any tumor that expresses tumor antigen MAGE-A. This treatment can be targeted to cancers that has a high expression of the MAGE-A antigen including, breast, colon, pancreas, glioblastoma, and esophageal squamous cell carcinomas, for example. The company expects to focus on developing the treatment for triple negative breast cancer.
